Table 1.
Sites of disease and treatment history
| Patient | Prior treatment | Metastatic disease status on enrollment in study |
|---|---|---|
| 1 | Hysterectomy, BSO, debulked, Taxol, Carboplatin, Cisplatin, bone marrow transplant, etoposide | Lower abdominal s.c. mass, two inguinal nodules |
| 2 | THA/BSO, omentectomy, appendectomy, nodectomy, Taxol, Cisplatin, Topotecan, Hexamethylmelamine | Retroperitoneal and left cervical lymph nodes |
| 3 | Radical hysterectomy, debulked, Carboplatin, Cytoxan, Adriamycin, Mitoxantrane, Tamoxifen, etoposide, radiation | Liver and vaginal cuff |
| 4 | TAH/BSO Taxol, Carboplatin, Doxil, Topotecan, Gemzar | Perihepatic lesion, midabdominal s.c. nodule |
| 5 | TAH/BSO, Carboplatin, Cytoxan, Taxol, Topotecan | Perihepatic, ascites, sigmoid mass, omental disease |
| 6 | Debulked, Carboplatin, Taxol, Doxil | Pelvic mass, para-aortic adenopathy |
| 7 | TAH/BSO, debulked, Carboplatin, Taxol | Multiple sites periaortic retroperitoneal adenopathy |
| 8 | TAH/BSO, debulked, Cisplatin, Cytoxan, Carboplatin, Taxol, Topotecan, Doxel | Liver, pericolonic, pelvic lymph node |
| 9 | TAH/BSO, debulked, Carboplatin, Taxol, Cytoxan | Liver and rectal muscle mets |
| 10 | TAH/BSO, debulked, Carboplatin, Taxol, Cisplatin, Taxol, monoclonal vaccine, Tamoxifen | Omentum, peritoneal implants, diaphragm, right supraclavicular nodes, pelvis |
| 11 | TAH/BSO, omentectomy, appendectomy, pancreatic reduction, splenectomy, Cytoxan, Cisplatin, vincristine, Hexalen, etoposide, Taxol, Carboplatin, Adriamycin, Topotecan, Gemzar | Peritoneal implants, left pleural effusion, liver, retroperitoneal nodes |
| 12 | TAH/BSO, omentectomy, Taxol, Carboplatin, bone marrow transplant, Taxane, Doxil, Herceptin, Gemcitabine, Topotecan | Pelvic and mediastinal mets |
| 13 | Ovarian cystectomy, hysterectomy, pelvic lymphadenectomy, Taxotere, Carboplatin, Topotecan, Doxyl, Gemzar | Omentum, mediastinum |
| 14 | TAH/BSO, omentectomy, pelvic and para-aortic lymphadenectomy, Taxol, Cisplatin, external beam radiation, Topotecan, Thalidomide, etoposide, Hexalen | Epigastric intra-abdominal mass, right pelvic mass |
NOTE: Patients had advanced ovarian cancer with metastases to various sites. Before enrolling in the current study, total abdominal hysterectomy and bilateral salpingo-oophorectomy were done, and most patients had undergone debulking surgery (patients 1–8 enrolled in cohort 1 and patients 9–14 in cohort 2).
Abbreviations: TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy.